Berlin-based Aignostics, a leader in AI-driven pathology solutions, has secured €31 million in an oversubscribed Series B round led by ATHOS and supported by Mayo Clinic, HTGF, Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA Fund, and IBB Ventures. The funding brings Aignostics’ total raised capital to over €50 million.
Aignostics is using this investment to enhance its AI technology for target identification, translational research, and companion diagnostics (CDx). With plans to expand in the U.S., the company is strengthening its partnerships and developing intuitive products for applications like tumor microenvironment analysis and biomarker profiling.
Advertisement
Milestones and Strategic Partnerships
2024 has been a transformative year for Aignostics, marked by a strategic collaboration with Bayer and the release of its foundation AI model, RudolfV. CEO Viktor Matyas emphasized that this funding will help turn the algorithms into practical products, moving toward “generalizable AI” for pathology in real-world clinical settings.
The company, originally a Charité Berlin spin-out, focuses on transforming complex pathology data to support biopharma in drug discovery, clinical trials, and diagnostics, with clients including the Mayo Clinic. ATHOS’s Julian Zachmann praised the german startup for combining scientific rigor with industry-leading innovation.
